Research programme: NMDA receptor antagonists - Sosei R&DAlternative Names: AD-529; ED-1812; NMDA antagonists research programme - Arakis
Latest Information Update: 23 Aug 2007
At a glance
- Originator Sosei R&D
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Neuropathic pain; Pain
Most Recent Events
- 30 Aug 2005 Arakis has been acquired by Sosei
- 19 Apr 2005 Preclinical trials in Pain in United Kingdom (unspecified route)